MedCity News February 6, 2025
Regulators will have their work cut out for them under a new administration that has expressed an anti-regulatory preference. Republicans next year will control the White House, Senate and House. What will it all mean for pharmacy leaders?
From record-high drug shortages to the explosive popularity of GLP-1 medications and the intensifying battle over the 340B drug discount program, many of the biggest healthcare stories of 2024 centered on pharmacy issues.
Attorneys for both big pharma and the federal government will be busy in 2025. Regulators will have their work cut out for them under a new administration that has expressed an anti-regulatory preference. Republicans next year will control the White House, Senate and House. What will it all...
Today's Sponsors
Today's Sponsor